Efficacy and Safety of Coadministration of Rosuvastatin , Ezetimibe , and Colestimide in Heterozygous Familial Hypercholesterolemia

Aggressive low-density lipoprotein (LDL) cholesterol-lowering therapy is important for high-risk patients. However, sparse data exist on the impact of combined aggressive LDL cholesterol-lowering therapy in familial hypercholesterolemia (FH), particularly on side effects to changes in plasma coenzym...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	The American journal of cardiology 2012-02, Vol.109 (3), p.364-369
Hauptverfasser:	Kawashiri, Masa-aki, MD, Nohara, Atsushi, MD, Noguchi, Tohru, PhD, Tada, Hayato, MD, Nakanishi, Chiaki, MD, Mori, Mika, MD, Konno, Tetsuo, MD, Hayashi, Kenshi, MD, Fujino, Noboru, MD, Inazu, Akihiro, MD, Kobayashi, Junji, MD, Mabuchi, Hiroshi, MD, Yamagishi, Masakazu, MD
Format:	Artikel
Sprache:	eng
Schlagworte:	Aged Aged, 80 and over Anion Exchange Resins Anticholesteremic Agents - administration & dosage Azetidines - administration & dosage Biological and medical sciences Cardiology Cardiology. Vascular system Cardiovascular Cardiovascular disease Cholesterol, LDL - blood Cholesterol, LDL - drug effects Disorders of blood lipids. Hyperlipoproteinemia Dose-Response Relationship, Drug Drug therapy Drug Therapy, Combination Enzymes Epichlorohydrin - administration & dosage Ezetimibe Female Fluorobenzenes - administration & dosage Follow-Up Studies Heterozygote Humans Hydroxymethylglutaryl-CoA Reductase Inhibitors - administration & dosage Hyperlipoproteinemia Type II - blood Hyperlipoproteinemia Type II - drug therapy Hyperlipoproteinemia Type II - genetics Imidazoles - administration & dosage Low density lipoprotein Male Medical sciences Metabolic diseases Middle Aged Plasma Prospective Studies Pyrimidines - administration & dosage Resins, Synthetic - administration & dosage Rosuvastatin Calcium Sulfonamides - administration & dosage Treatment Outcome
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	Aggressive low-density lipoprotein (LDL) cholesterol-lowering therapy is important for high-risk patients. However, sparse data exist on the impact of combined aggressive LDL cholesterol-lowering therapy in familial hypercholesterolemia (FH), particularly on side effects to changes in plasma coenzyme Q10 and proprotein convertase subtilisin/kexin type 9 levels. We enrolled 17 Japanese patients with heterozygous FH (12 men, 63.9 ± 7.4 years old) with single LDL receptor gene mutations in a prospective open randomized study. Permitted maximum doses of rosuvastatin (20 mg/day), ezetimibe (10 mg/day), and granulated colestimide (3.62 g/day) were introduced sequentially. Serum levels of LDL cholesterol decreased significantly by −66.4% (p
ISSN:	0002-9149 1879-1913
DOI:	10.1016/j.amjcard.2011.09.019